

Cover Story
Regulatory News
By Jacquelyn Cobb and Paul Goldberg
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- NCI releases names of members of ad hoc working group—filling the void left by BSA
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.” - Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines - NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium